{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:21Z","timestamp":1791465081602,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early after the beginning of the coronavirus disease 2019 (COVID-19)-pandemic, it was observed that critically ill patients in the intensive care unit (ICU) were susceptible to developing secondary fungal infections, particularly COVID-19 associated pulmonary aspergillosis (CAPA). Here we report our local experience on the impact of mold active antifungal prophylaxis on CAPA occurrence in critically ill COVID-19 patients. This is a monocentric, prospective cohort study including all consecutive patients with COVID-19 associated acute respiratory failure who were admitted to our local medical ICU. Based on the treating physician\u2019s discretion, patients may have received antifungal prophylaxis or not. All patients were retrospectively characterized as having CAPA according to the 2020 ECMM\/ISHAM consensus definitions. Seventy-seven patients were admitted to our medical ICU during April 2020 and May 2021 and included in the study. The majority of patients received invasive-mechanical ventilation (61%). Fifty-three patients (68.8%) received posaconazole prophylaxis. Six cases of probable CAPA were diagnosed within clinical routine management. All six cases were diagnosed in the non-prophylaxis group. The incidence of CAPA in the overall study cohort was 0.57 events per 100 ICU days and 2.20 events per 100 ICU days in the non-prophylaxis group. No difference of cumulative 84-days survival could be observed between the two groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.115). In this monocentric cohort, application of posaconazole prophylaxis in patients with COVID-19 associated respiratory failure did significantly reduce the rate of CAPA.\n                  <\/jats:p>","DOI":"10.1007\/s11046-023-00809-y","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T05:02:19Z","timestamp":1705122139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["COVID-19 associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit: Impact of Antifungal Prophylaxis"],"prefix":"10.1007","volume":"189","author":[{"given":"Jonas","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Gornicec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-5695","authenticated-orcid":false,"given":"Alexander C.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-3646","authenticated-orcid":false,"given":"Philipp","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5751-9311","authenticated-orcid":false,"given":"Juergen","family":"Prattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"issue":"12","key":"809_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S2213-2600(22)00259-4","volume":"10","author":"S Feys","year":"2022","unstructured":"Feys S, Gon\u00e7alves SM, Khan M, Choi S, Boeckx B, Chatelain D, et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med. 2022;10(12):1147\u201359.","journal-title":"Lancet Respir Med."},{"issue":"10","key":"809_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782\u201392.","journal-title":"Lancet Respir Med."},{"issue":"10223","key":"809_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497\u2013506.","journal-title":"China Lancet."},{"issue":"5","key":"809_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475\u201381.","journal-title":"Lancet Respir Med."},{"issue":"8","key":"809_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","volume":"7","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127\u201340.","journal-title":"Nat Microbiol."},{"key":"809_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mib.2021.04.006","volume":"62","author":"IM Dewi","year":"2021","unstructured":"Dewi IM, Janssen NA, Rosati D, Bruno M, Netea MG, Br\u00fcggemann RJ, et al. Invasive pulmonary aspergillosis associated with viral pneumonitis. Curr Opin Microbiol. 2021;62:21\u20137.","journal-title":"Curr Opin Microbiol."},{"issue":"8","key":"809_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","volume":"38","author":"RL Chua","year":"2020","unstructured":"Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, et al. COVID-19 severity correlates with airway epithelium\u2013immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970\u20139.","journal-title":"Nat Biotechnol."},{"issue":"674","key":"809_CR8","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1126\/scitranslmed.abq6682","volume":"14","author":"N Sarden","year":"2022","unstructured":"Sarden N, Sinha S, Potts KG, Pernet E, Hiroki CH, Hassanabad MF, et al. A B1a\u2013natural IgG\u2013neutrophil axis is impaired in viral- and steroid-associated aspergillosis. Sci Transl Med. 2022;14(674):6682.","journal-title":"Sci Transl Med."},{"issue":"3","key":"809_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tim.2023.01.008","volume":"31","author":"JP Gangneux","year":"2023","unstructured":"Gangneux JP, Hoenigl M, Papon N. How to lose resistance to aspergillus infections. Trends Microbiol. 2023;31(3):222\u20134.","journal-title":"Trends Microbiol."},{"issue":"2","key":"809_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","volume":"10","author":"JP Gangneux","year":"2022","unstructured":"Gangneux JP, Dannaoui E, Fekkar A, Luyt CE, Botterel F, De Prost N, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022;10(2):180\u201390.","journal-title":"Lancet Respir Med."},{"issue":"4","key":"809_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/jof8040390","volume":"8","author":"M Egger","year":"2022","unstructured":"Egger M, Bussini L, Hoenigl M, Bartoletti M. Prevalence of COVID-19-associated pulmonary aspergillosis: critical review and conclusions. J Fungi. 2022;8(4):390.","journal-title":"J Fungi."},{"issue":"4","key":"809_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","volume":"28","author":"J Prattes","year":"2021","unstructured":"Prattes J, Wauters J, Giacobbe DR, Salmanton-Garc\u00eda J, Maertens J, Bourgeois M, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients\u2014a multinational observational study by the European confederation of medical mycology. Clin Microbiol Infect. 2021;28(4):580\u20137.","journal-title":"Clin Microbiol Infect."},{"issue":"10","key":"809_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00134-021-06471-6","volume":"47","author":"J Prattes","year":"2021","unstructured":"Prattes J, Wauters J, Giacobbe DR, Lagrou K, Hoenigl M, et al. Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Med. 2021;47(10):1158\u201360.","journal-title":"Intensive Care Med."},{"issue":"8","key":"809_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","volume":"47","author":"PE Verweij","year":"2021","unstructured":"Verweij PE, Br\u00fcggemann RJM, Azoulay E, Bassetti M, Blot S, Buil JB, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021;47(8):819\u201334.","journal-title":"Intensive Care Med."},{"issue":"1","key":"809_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13054-021-03753-9","volume":"25","author":"S Hatzl","year":"2021","unstructured":"Hatzl S, Reisinger AC, Posch F, Prattes J, Stradner M, Pilz S, et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit Care. 2021;25(1):335.","journal-title":"Crit Care"},{"issue":"5","key":"809_CR16","doi-asserted-by":"publisher","first-page":"e0696","DOI":"10.1097\/CCE.0000000000000696","volume":"4","author":"M Melchers","year":"2022","unstructured":"Melchers M, van Zanten ARH, Heusinkveld M, Leeuwis JW, Schellaars R, Lammers HJW, et al. Nebulized amphotericin b in mechanically ventilated COVID-19 patients to prevent invasive pulmonary aspergillosis: a retrospective cohort study. Crit Care Explor. 2022;4(5):e0696.","journal-title":"Crit Care Explor"},{"issue":"1","key":"809_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13054-021-03728-w","volume":"25","author":"S Van Ackerbroeck","year":"2021","unstructured":"Van Ackerbroeck S, Rutsaert L, Roelant E, Dillen K, Wauters J, Van Regenmortel N. Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis\/aspergillus tracheobronchitis. Crit Care. 2021;25(1):298.","journal-title":"Crit Care"},{"issue":"2","key":"809_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4187\/respcare.09405","volume":"67","author":"BK Saha","year":"2022","unstructured":"Saha BK, Saha S, Chong WH, Beegle S. Indications, clinical utility, and safety of bronchoscopy in COVID-19. Respir Care. 2022;67(2):241\u201351.","journal-title":"Respir Care"},{"key":"809_CR19","first-page":"ciad546","volume":"11","author":"S Feys","year":"2023","unstructured":"Feys S, Lagrou K, Lauwers HM, Haenen K, Jacobs C, Brusselmans M, et al. High burden of COVID-19-associated pulmonary aspergillosis (CAPA) in severely immunocompromised patients requiring mechanical ventilation. Clin Infect Dis. 2023;11:ciad546.","journal-title":"Clin Infect Dis."},{"key":"809_CR20","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","volume":"21","author":"P Koehler","year":"2020","unstructured":"Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020;21:e149.","journal-title":"Lancet Infect Dis."},{"key":"809_CR21","doi-asserted-by":"publisher","first-page":"e02298","DOI":"10.1128\/jcm.02298-21","volume":"60","author":"DR Giacobbe","year":"2022","unstructured":"Giacobbe DR, Prattes J, Wauters J, Dettori S, Signori A, Salmanton-Garc\u00eda J, et al. Prognostic impact of bronchoalveolar lavage fluid galactomannan and aspergillus culture results on survival in COVID-19 intensive care unit patients: a post hoc analysis from the european confederation of medical mycology (ECMM) COVID-19-associated pulmonary aspergillosis study. J Clin Microbiol. 2022;60:e02298-21.","journal-title":"J Clin Microbiol."},{"key":"809_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Perfect J, Helfgott D, Goh YT, Suresh R. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348.","journal-title":"N Engl J Med."},{"key":"809_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Langston A, Reddy V. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335.","journal-title":"N Engl J Med."},{"issue":"2","key":"809_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1086\/515128","volume":"28","author":"C Rotstein","year":"1999","unstructured":"Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999;28(2):331\u201340.","journal-title":"Clin Infect Dis."},{"issue":"24","key":"809_CR25","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","volume":"116","author":"JR Wingard","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111\u20138.","journal-title":"Blood"},{"issue":"2","key":"809_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1086\/515129","volume":"28","author":"F Menichetti","year":"1999","unstructured":"Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind. Multicenter Trial Clin Infect Dis. 1999;28(2):250\u20135.","journal-title":"Multicenter Trial Clin Infect Dis."},{"issue":"5","key":"809_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1164\/rccm.201910-1931OC","volume":"202","author":"R Nyga","year":"2020","unstructured":"Nyga R, Maizel J, Nseir S, Chouaki T, Milic I, Roger PA, et al. Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza. A Clinical Trial Am J Respir Crit Care Med. 2020;202(5):708\u201316.","journal-title":"A Clinical Trial Am J Respir Crit Care Med."},{"issue":"6","key":"809_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00134-021-06431-0","volume":"47","author":"L Vanderbeke","year":"2021","unstructured":"Vanderbeke L, Janssen NAF, Bergmans DCJJ, Bourgeois M, Buil JB, Debaveye Y, et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. 2021;47(6):674\u201386.","journal-title":"Intensive Care Med."},{"issue":"12","key":"809_CR29","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/jac\/dkx263","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, et al. Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017;72(12):3406\u201313.","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"809_CR30","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/jac\/dkab012","volume":"76","author":"R Van Daele","year":"2021","unstructured":"Van Daele R, Br\u00fcggemann RJ, Dreesen E, Depuydt P, Rijnders B, Cotton F, et al. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2021;76(5):1234\u201341.","journal-title":"J Antimicrob Chemother."},{"issue":"12","key":"809_CR31","doi-asserted-by":"publisher","first-page":"e01229","DOI":"10.1128\/JCM.01229-21","volume":"59","author":"M Erg\u00fcn","year":"2021","unstructured":"Erg\u00fcn M, Br\u00fcggemann RJM, Alanio A, Delli\u00e8re S, van Arkel A, Bentvelsen RG, et al. Aspergillus test profiles and mortality in critically Ill COVID-19 patients. J Clin Microbiol. 2021;59(12):e01229-21.","journal-title":"J Clin Microbiol."},{"issue":"3","key":"809_CR32","doi-asserted-by":"publisher","first-page":"e02169","DOI":"10.1128\/jcm.02169-21","volume":"60","author":"S Delli\u00e8re","year":"2022","unstructured":"Delli\u00e8re S, Dudoignon E, Voicu S, Collet M, Fodil S, Plaud B, et al. Combination of mycological criteria: a better surrogate to identify COVID-19-associated pulmonary aspergillosis patients and evaluate prognosis? J Clin Microbiol. 2022;60(3):e02169-e2221.","journal-title":"J Clin Microbiol."},{"issue":"7","key":"809_CR33","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.4049\/jimmunol.1303049","volume":"192","author":"K Sun","year":"2014","unstructured":"Sun K, Metzger DW. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant staphylococcus aureus infection. J Immunol. 2014;192(7):3301\u20137.","journal-title":"J Immunol."},{"issue":"3","key":"809_CR34","doi-asserted-by":"publisher","first-page":"e01859","DOI":"10.1128\/jcm.01859-22","volume":"61","author":"M Hoenigl","year":"2023","unstructured":"Hoenigl M, Egger M, Price J, Krause R, Prattes J, White PL. Metagenomic next-generation sequencing of plasma for diagnosis of COVID-19-associated pulmonary aspergillosis. J Clin Microbiol. 2023;61(3):e01859-22.","journal-title":"J Clin Microbiol."},{"issue":"4","key":"809_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/myc.13254","volume":"64","author":"EFJ Meijer","year":"2021","unstructured":"Meijer EFJ, Dofferhoff ASM, Hoiting O, Meis JF. COVID-19\u2013associated pulmonary aspergillosis: a prospective single-center dual case series. Mycoses. 2021;64(4):457\u201364.","journal-title":"Mycoses."},{"issue":"7","key":"809_CR36","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/ciaa007","volume":"71","author":"IS Schwartz","year":"2020","unstructured":"Schwartz IS, Friedman DZP, Zapernick L, Dingle TC, Lee N, Sligl W, et al. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta. Canada Clin Infect Dis. 2020;71(7):1760\u20133.","journal-title":"Canada Clin Infect Dis."},{"issue":"2","key":"809_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S2213-2600(21)00500-2","volume":"10","author":"PE Verweij","year":"2022","unstructured":"Verweij PE, Van De Veerdonk FL. Managing secondary fungal infections in severe COVID-19: how to move forward? Lancet Respir Med. 2022;10(2):127\u20138.","journal-title":"Lancet Respir Med."}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-023-00809-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-023-00809-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-023-00809-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T12:20:47Z","timestamp":1709209247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-023-00809-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1007\/s11046-023-00809-y","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.H. received research funding from Gilead, Astellas, MSD, Euroimmune, Scynexis, F2G and Pfizer, outside of the submitted work. J.P. has received speakers\u2019 fees from Gilead Sciences, Pfizer, Swedish Orphan Biovitrum, Associated of Cape Cod, served at advisor boards for Gilead Sciences and Pfizer and holds stocks of Novo Nordisk and AbbVie Inc\u2013all outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local ethics committee (32\u2013296 ex 19\/20).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"According to our local ethics committee regulations, informed consent form was obtained from all patients, whenever possible.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publications"}}],"article-number":"3"}}